| |
Where customer experience is our priority. Together with Fortrea –exceptional is possible. Experience Agility. .png)
|
|
Today’s Big NewsDec 20, 2023 |
|
Slope's white paper reveals a breakthrough solution: software-guided sample workflows that ensure site compliance and keep your studies on track. Read more. 
|
|
| By James Waldron The antibody-drug conjugate (ADC) fever of recent months still shows no signs of abating, with GSK heading back to Hansoh Pharmaceutical to pick up another candidate for $185 million upfront. |
|
|
|
By Gabrielle Masson With Sanofi Ventures in tow, Sudo Biosciences has secured $116 million to advance programs in multiple sclerosis and psoriasis into the clinic. |
By James Waldron Aclaris Therapeutics has decided to give its MK2 inhibitor zunsemetinib a second chance—unfortunately, almost half of the biotech’s workforce won’t be so lucky. |
By Annalee Armstrong Small immunotherapy biotech Asher Bio has reduced its workforce by 60%, sending 34 employees on their way and pivoting to focus on a single immunotherapy. Chief Operating Officer Kyle Elrod confirmed the layoffs to Fierce Biotech Tuesday afternoon. |
By James Waldron Less than a week after the first-ever request for approval of an MDMA treatment landed on the FDA’s desk, Compass Pathways has reported phase 2 safety data from the first clinical trial of psilocybin in post-traumatic stress disorder (PTSD). |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Joseph Keenan Clemson Rural Health, a unit of Clemson University’s College of Behavioral, Social and Health Sciences, is linking up with Seattle-based CRO Precia Group to bring more clinical trials to underserved rural populations. |
By Kevin Dunleavy Seven months after Krystal Biotech became the first company to gain FDA approval to treat the rare, devastating skin disease epidermolysis bullosa (EB), Chiesi Farmaceutici has followed suit. On Tuesday, the U.S. regulator gave a thumbs up to Chiesi’s Filsuvez (birch triterpenes) to treat both junctional epidermolysis bullosa (JEB) and dystrophic epidermolysis bullosa (DEB) in patients 6 months and older. |
By Noah Tong Only a small fraction of health plans and value-based care organizations have a fully developed care management model for its enrollees with dementia or Alzheimer's, a new survey shows. |
By Conor Hale We're looking for the fiercest and most innovative private medtech companies and startups from around the globe and in every healthcare area for our annual list of the Fierce 15. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," Dr. Nigam Shah, Chief Data Scientist at Stanford Health Care, shares insights into the direction of the industry and anticipated developments as AI adoption gains momentum. |
|
|---|
|
|
Whitepaper Download this whitepaper to discover the 3 pillars of successful PK testing and conquer bioanalytical challenges. Sponsored by: Sannova Analytical |
Whitepaper The road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. S3 Connected Health |
Whitepaper qPCR Assay Design - Quantify microbial biomarkers with high sensitivity and dynamic range Sponsored by: Diversigen |
Whitepaper Streamline your clinical cell therapy with our GMP-compliant ribonucleoprotein (RNP) manufacturing as you scale up without compromising on quality to tackle complex regulatory requirements. Sponsored by: Aldevron |
Executive Summary By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper Learn about the untapped power of AI-driven insights — where innovation meetings precision, effortlessly unlocking benefits for your organization. Sponsored by: Planisware |
Whitepaper Medical devices & consumer wearables are starting to overlap, creating risks & opportunities for traditional medical device companies as well as consumer wearables manufacturers. This paper explores pros and cons from both perspectives. Sponsored by: Blue Matter Consulting |
Whitepaper Improving efficiency and productivity in biologics manufacturing is a longstanding goal within today’s industry, especially now as new and increasingly complex molecules are fundamentally changing technological and operational approaches to drug development. Process intensification can help accelerate this pace of innovation through advanced process development techniques and high productivity manufacturing platforms. Sponsored by: Lonza |
Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| |
|
